---
title: "Top 10 US Stock Losers (10.20)"
description: "HCM II Acquisition(HOND) fell 12.42%, with a trading turnover 142.7 Million USD, and a year-to-date rose 126.5%. Exelixis(EXEL) fell 12%, with a trading turnover 324.5 Million USD, and a year-to-date "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261943891.md"
published_at: "2025-10-20T22:01:11.000Z"
---

# Top 10 US Stock Losers (10.20)

> HCM II Acquisition(HOND) fell 12.42%, with a trading turnover 142.7 Million USD, and a year-to-date rose 126.5%. Exelixis(EXEL) fell 12%, with a trading turnover 324.5 Million USD, and a year-to-date rose 3.7%. BTQ Tech(BTQ) fell 10.46%, with a trading turnover 100.6 Million USD, and a year-to-date rose 58.4%.

NASDAQ Composite Index has rose 1.37%, with a year-to-date rose 19.1%; S&P 500 has rose 1.07%, with a year-to-date rose 14.5%; Dow Jones Industrial Average has rose 1.12%, with a year-to-date rose 9.8%.

HCM II Acquisition(HOND) fell 12.42%, with a trading turnover 142.7 Million USD, and a year-to-date rose 126.5%.

Exelixis(EXEL) fell 12%, with a trading turnover 324.5 Million USD, and a year-to-date rose 3.7%.

BTQ Tech(BTQ) fell 10.46%, with a trading turnover 100.6 Million USD, and a year-to-date rose 58.4%.

### Related Stocks

- [HOND.US - HCM II Acquisition](https://longbridge.com/en/quote/HOND.US.md)
- [EXEL.US - Exelixis](https://longbridge.com/en/quote/EXEL.US.md)
- [BTQ.US - BTQ Tech](https://longbridge.com/en/quote/BTQ.US.md)
- [QBTS.US - D-Wave Quantum](https://longbridge.com/en/quote/QBTS.US.md)
- [GKOS.US - Glaukos](https://longbridge.com/en/quote/GKOS.US.md)
- [GMAB.US - Genmab A/S](https://longbridge.com/en/quote/GMAB.US.md)
- [PRAX.US - Praxis Precision Medicines](https://longbridge.com/en/quote/PRAX.US.md)
- [CBRL.US - CBRL](https://longbridge.com/en/quote/CBRL.US.md)
- [CRWV.US - Coreweave](https://longbridge.com/en/quote/CRWV.US.md)
- [ELF.US - ELF Beauty](https://longbridge.com/en/quote/ELF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股盘前热门交易：Coreweave 盘前跌 3.63%；Strategy 盘前跌 3.40% | Coreweave 盘前跌 3.63%；Strategy 盘前跌 3.40%；TG-17 盘前涨 183.07%；Leifras 盘前涨 42.15%；麦斯莫医疗盘前涨 37.14%。 | [Link](https://longbridge.com/en/news/276114896.md) |
| EXEL 工业公司报告称，截至 2026 年 1 月，公司拥有 679 万股和 989 万投票权 | EXEL Industries SA 报告称，截至 2026 年 1 月 31 日，其股本中拥有 6,787,900 股股份。该公司拥有 9,890,341 个理论投票权，扣除无投票权股份后，实际可行使的投票权为 9,884,832 个。该 | [Link](https://longbridge.com/en/news/275592323.md) |
| HC Wainwright 对 Genmab A/S（GMAB）持看涨态度，原因是 DARZALEX 的销售表现强劲 | H.C. Wainwright 重申了对 Genmab A/S（NASDAQ:GMAB）的买入评级，目标价为 39 美元，理由是预计 2025 年 DARZALEX 的净销售额强劲。Genmab 被认为是当前值得购买的高增长国际股票之一，此 | [Link](https://longbridge.com/en/news/275885478.md) |
| 展望 Genmab 未来的收益情况 | Genmab（纳斯达克代码：GMAB）将于 2026 年 2 月 17 日公布季度财报，分析师预计每股收益（EPS）为 0.44 美元。投资者期待在之前每股收益超出预期 0.19 美元后，能够获得积极的指引，这导致股价下跌了 0.62%。截 | [Link](https://longbridge.com/en/news/276064631.md) |
| Genmab：去风险的长期发展前景以及 2026 年临床催化剂支持买入评级，目标价为 2,650 丹麦克朗 | Jefferies 分析师 Benjamin Jackson 对 Genmab A/S 维持买入评级，目标价为 2,650 丹麦克朗。他指出，增强的增长前景和在 2029 年后对 Darzalex 版税的依赖减少是关键因素。即将到来的 20 | [Link](https://longbridge.com/en/news/276089857.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.